Clinical Trial Detail

NCT ID NCT03273153
Title A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Hoffmann-La Roche
Indications

melanoma

Therapies

Pembrolizumab

Atezolizumab + Cobimetinib

Age Groups: adult senior

Additional content available in CKB BOOST